Related questions this article answers
- Is UnitedHealth stock overvalued right now?
- Is UNH undervalued?
- Should I buy UnitedHealth stock?
- Is now a good time to buy UNH?
- What is UnitedHealth's fair value?
- Is UNH a good long term investment?
The short answer
Short answer: UnitedHealth looks fairly priced at current levels. With the stock trading near $379.98, UNH is priced around 23.1x trailing earnings, 0.6x sales, and 15.4x EV/EBITDA, while free cash flow yield near 5.8% helps support the valuation. That makes the stock expensive enough to respect, but not obviously overpriced for a business of this quality.
Why valuing this kind of healthcare company is more complex than it looks
UnitedHealth sits in healthcare, but it should be read as a diversified healthcare platform. Investors care about scale, margin durability, and how well cash flow holds up across different cycles.
The reason this matters is simple. Two companies can show similar headline multiples and still deserve very different valuations because their margins, cash conversion, and growth durability are not the same.
The 5 key metrics applied to UnitedHealth
A single ratio rarely tells the whole story. This framework starts with trailing P/E, forward P/E, PEG, EV/EBITDA, and price to sales, then keeps only the metrics that are present and usable for this company.
Trailing P/E
Trailing P/E compares the current share price with the last twelve months of earnings. For UnitedHealth, the current reading is 23.1x. Shows what the market is paying for UnitedHealth's recent earnings.
Forward P/E
Forward P/E uses expected earnings instead of trailing earnings. For UnitedHealth, the current reading is 41.8x. Shows how the market is valuing UnitedHealth's expected earnings.
EV/EBITDA
EV/EBITDA compares enterprise value with operating profit before depreciation and amortization. For UnitedHealth, the current reading is 15.4x. Adds a capital structure aware check on operating valuation.
Price to sales
Price to sales compares market value with revenue. For UnitedHealth, the current reading is 0.6x. Useful when revenue mix, margins, or future scaling matter as much as near term earnings.
Free cash flow yield
Free cash flow yield compares free cash flow with market value. For UnitedHealth, the current reading is 5.8%. Shows how much cash UnitedHealth is generating relative to its market value.
| Metric | Current value | What it suggests |
|---|---|---|
| Trailing P/E | 23.1x | Shows what the market is paying for UnitedHealth's recent earnings. |
| Forward P/E | 41.8x | Shows how the market is valuing UnitedHealth's expected earnings. |
| EV/EBITDA | 15.4x | Adds a capital structure aware check on operating valuation. |
| Price to sales | 0.6x | Useful when revenue mix, margins, or future scaling matter as much as near term earnings. |
| Free cash flow yield | 5.8% | Shows how much cash UnitedHealth is generating relative to its market value. |
| Gross margin | 18.5% | Shows how much of UnitedHealth's revenue remains after direct costs. |
| Revenue growth | 11.8% | Shows whether UnitedHealth's top line is still expanding. |
The table is a snapshot of the current setup. It is meant to frame the valuation question, not replace the company specific analysis below.
UnitedHealth's valuation breakdown
As of Q2 2026, UnitedHealth traded near $379.98 with a market value near $277.75B.
| Metric | Current value | What it suggests |
|---|---|---|
| Trailing P/E | 23.1x | Shows what the market is paying for UnitedHealth's recent earnings. |
| Forward P/E | 41.8x | Shows how the market is valuing UnitedHealth's expected earnings. |
| EV/EBITDA | 15.4x | Adds a capital structure aware check on operating valuation. |
| Price to sales | 0.6x | Useful when revenue mix, margins, or future scaling matter as much as near term earnings. |
| Free cash flow yield | 5.8% | Shows how much cash UnitedHealth is generating relative to its market value. |
| Gross margin | 18.5% | Shows how much of UnitedHealth's revenue remains after direct costs. |
| Revenue growth | 11.8% | Shows whether UnitedHealth's top line is still expanding. |
Metrics move with the market and with each earnings update. If a field is missing or stale, it is intentionally left out here rather than guessed.
What the numbers tell us
UnitedHealth is being valued like a large healthcare platform rather than a simple insurer. Trailing P/E near 23.1x, price to sales near 0.6x, and free cash flow yield near 5.8% show why the market still gives the business real credit for scale and cash generation.
- UnitedHealth's forward P/E is not offering much relief versus the trailing multiple, so the market may still be paying up before the earnings improvement is fully visible.
- UnitedHealth's price to sales multiple near 0.6x needs to be read beside revenue growth near 11.8%, because rich revenue multiples only hold up when growth quality stays intact.
- UnitedHealth's gross margin near 18.5% helps explain whether the market is dealing with a commodity style business or a business with stronger pricing power and business mix.
UnitedHealth's competitive position
UnitedHealth's edge is its scale across insurance and healthcare services. That matters because a broad platform like this can produce steadier earnings and cash flow than a narrow payer business.
What would make UnitedHealth look cheaper or more expensive?
What would make it look cheaper
- UnitedHealth would look cheaper if earnings growth improved while the valuation multiple stayed muted.
- UnitedHealth would also look more attractive if cash flow kept compounding while the share price stayed flat.
What would make it look expensive
- UnitedHealth would look more expensive if growth slowed while the market kept paying for quality.
- UnitedHealth would also look expensive if margin pressure built before the stock had a chance to reset.
Healthcare valuation context
UnitedHealth sits in healthcare, but it should be read as a diversified healthcare platform. Investors care about scale, margin durability, and how well cash flow holds up across different cycles.
The verdict
UnitedHealth looks close to a market level that already reflects much of the current business strength. Future upside is more likely to come from better fundamentals than from simple multiple expansion. UnitedHealth usually deserves a decent premium because of scale and cash generation, but the current price already reflects much of that strength.
This is analysis of publicly available market data. It is not financial advice, and it should be read in the context of personal goals, risk tolerance, and time horizon.
Want to run the numbers yourself?
Use TopTier Strategy research tools to review UNH's live valuation profile, stock page, and related company analysis.
Frequently asked questions
Is UnitedHealth stock overvalued in 2026?
Is UnitedHealth a good stock to buy right now?
What is UnitedHealth's fair value?
Can you value UnitedHealth just on P/E?
Where can I analyze UNH with current data?
Data source: TopTier Strategy research platform - toptierstrategy.com/research. Data as of 2026-05-10T16:57:45.587833.